Hutchmed China has completed patient enrollment in its phase three lung cancer trial, a major milestone for the biopharmaceutical company.
AstraZeneca raised its dividend after strong drug sales drove higher earnings in the first half of 2025.
showbiz sport money travel garden news tech health science business politics culture environment